CSBTF (Kuros Biosciences) Net Income From Continuing Operations: $10.8 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSBTF Kuros Biosciences Ltd CSBTF
76 GF Score
Price $26.99
GF Value $43.46
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Kuros Biosciences Net Income From Continuing Operations?

Kuros Biosciences CSBTF 76 Net Income From Continuing Operations is $10.8 Mil as of Jun. 2026. GuruFocus rates CSBTF with a GF Score™ of 76/100 and a GF Value™ of $43.46 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Kuros Biosciences's net income from continuing operations for the six months ended in Jun. 2026 was $5.9 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2026 was $10.8 Mil.

Kuros Biosciences Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Kuros Biosciences's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kuros Biosciences Net Income From Continuing Operations Chart

Kuros Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.45 -17.25 -15.89 -4.42 5.10

Kuros Biosciences Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.23 -5.65 0.16 4.94 5.88
CSBTF
76GF Score
Kuros Biosciences Ltd CSBTF
Net Income From Continuing Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kuros Biosciences Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $10.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of $10.8 Mil mean?
Kuros Biosciences (CSBTF) has a Net Income From Continuing Operations of $10.8 Mil as of Jun. 2026. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Kuros Biosciences and its competitors.
Is Kuros Biosciences' Net Income From Continuing Operations too high?
Kuros Biosciences' current Net Income From Continuing Operations is $10.8 Mil. Overall, Kuros Biosciences has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Net Income From Continuing Operations compare to ABT and SYK?
Kuros Biosciences' Net Income From Continuing Operations of $10.8 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Medical Devices & Instruments company?
A good Net Income From Continuing Operations depends on the Medical Devices & Instruments industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Kuros Biosciences and its competitors. Kuros Biosciences's current Net Income From Continuing Operations is $10.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $43.46, compared to a current price of $26.99 — trading 37.9% below its estimated fair value. The current Net Income From Continuing Operations is $10.8 Mil. Kuros Biosciences' overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Net Income From Continuing Operations is $10.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kuros Biosciences (CSBTF) Overvalued in 2026?

Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued. The current stock price of $26.99 is trading 37.9% below its estimated GF Value™ of $43.46. GuruFocus considers Kuros Biosciences to be Significantly Undervalued.

Key valuation signals for CSBTF:

  • Net Income From Continuing Operations: $10.8 Mil
  • GF Value™: $43.46 vs. price of $26.99 (37.9% below fair value)
  • GF Score™: 76/100 with 1 warning sign

No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kuros Biosciences Business Description

Address Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
76GF Score

Get the complete analysis for CSBTF

Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.99
Price
$43.46
GF Value